ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Lupus nephritis"

  • Abstract Number: 1841 • ACR Convergence 2024

    Preclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases

    Kristen Zhang, Joanne Li, Duy Nguyen, Nguyen Tan, Hsin-Yuan Cheng, David Huang, Suhasni Gopalakrishnan, Zachary Roberts, Cesar Sommer and Elvin Lauron, Allogene Therapeutics, South San Francisco, CA

    Background/Purpose: Autologous CD19 chimeric antigen receptor (CAR) T cell therapies have recently shown to be well tolerated and highly effective in patients with autoimmune diseases…
  • Abstract Number: 2550 • ACR Convergence 2024

    Infiltrating and Resident Macrophages in Lupus Nephritis: Scar Associated Macrophage Phagocytic Dysfunction and Fibroblast Activation

    Chirag Raparia1, Paul Hoover2, Arnon Arazi3, Nir Hacohen4 and Anne Davidson5, 1Donald and Barbara Zucker School of Medicine At Hofstra/Northwell, Shoreham, NY, 2Brigham and Women's Hospital, SWAMPSCOTT, MA, 3Feinstein Institutes for Medical Research, Melrose, MA, 4Broad Institute of MIT and Harvard, Boston, MA, 5Feinstein Institutes for Medical Research, Manhasset, NY

    Background/Purpose: Lupus nephritis (LN) is driven by a heterogeneous population of renal macrophages. We have previously reported that the renal macrophage subpopulations are similar in…
  • Abstract Number: 0008 • ACR Convergence 2024

    Preclinical Development and Manufacturability of KYV-201, an Investigational Allogeneic Anti-CD19 Chimeric Antigen Receptor T Cell for the Treatment of Autoimmune Disease

    Ashley Mahne1, Ryan Rodriguez2, Jessica Wang1, Daniel Anaya1, Joseph K. Cheng1, Brandon Kwong1, Jesus Banuelos3, Peter Starokadomskyy3, Soo Park3, Candice Gibson4, Shouvonik Sengupta1, Simone Sandoval1, Jazmin Bravo3, Jeanne Flandez1, Shairaz Shah1, Amanda Goodsell1, Nicole Khoshnoodi1, Jennifer Zeng1, Santiago Foos-Russ1, Mario Lorente1, Jennifer Adrian1, Timothy Klasson1, Yong Zhang5, Jessica Seitzer6, Birgit Schultes5 and Tom Van Blarcom3, 1Kyverna Therapeutics, Inc., Emeryville, CA, 2Kyverna Therapeutics, Inc., Emerville, CA, 3Kyverna Therapeutics, Inc., Emeryville, 4Kyverna Therapeutics, Inc., Emerybille, 5Intellia Therapeutics, Inc., Cambridge, MA, 6Intellia Therapeutics, Inc., Cambridge

    Background/Purpose: Autologous anti-CD19 chimeric antigen receptor (CAR) T cells show early clinical evidence of safety and efficacy for treating several autoimmune diseases (Müller F. N Engl…
  • Abstract Number: 0640 • ACR Convergence 2024

    7000-Plex Proteomic Screen of Urine for Flare Monitoring and Treatment Response Biomarkers in Active Lupus Nephritis

    kamala Vanarsa1, Yewei Ma2, Mohammad Daouk2, Vinaika Maruvada2, Ramesh Saxena3 and Chandra Mohan4, 1University of Houston, houstton, 2University of Houston, Houston, 3UT Southwestern Medical Center, Dallas, 4University of Houston, Houston, TX

    Background/Purpose: Lupus nephritis (LN) is a major cause of morbidity and mortality in patients with lupus. Since the kidney biopsy is invasive, better, more predictive…
  • Abstract Number: 0811 • ACR Convergence 2024

    High-Throughput Proteomic Profiling of Longitudinal Serum Samples to Predict Treatment Response in Lupus Nephritis

    Benjamin Jones1, Rufei Lu2, Andrea Fava3, Peter Izmirly4, Jennifer Anolik5, Chaim Putterman6, David Wofsy7, Matthias Kretzler8, Celine Berthier9, E. Steven Woodle10, Michael Weisman11, Mariko Ishimori12, The Accelerating medicines Partnership: RA/SLE Network13, Betty Diamond14, Jill Buyon15, Michelle Petri16, Judith James13 and Joel Guthridge13, 1Oklahoma State University, Oklahoma City, OK, 2University of California San Francisco, San Bruno, CA, 3Johns Hopkins University, Baltimore, MD, 4New York University Grossman School of Medicine, New York, NY, 5University of Rochester Medical Center, Rochester, NY, 6Albert Einstein College of Medicine, Safed, Israel, 7University of California San Francisco, SF, CA, 8University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, 9University of Michigan, Ann Arbor, MI, 10University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cinncinnati, OH, 11Stanford University, Los Angeles, CA, 12Cedars-Sinai Health System, Los Angeles, CA, 13Oklahoma Medical Research Foundation, Oklahoma City, OK, 14The Feinstein Institutes for Medical Research, Manhasset, NY, 15NYU Grossman School of Medicine, New York, NY, 16Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: Lupus nephritis (LN) can lead to severe morbidity and early mortality in SLE patients. While therapeutic options for LN have improved, they are not…
  • Abstract Number: 1536 • ACR Convergence 2024

    Prescription Rates of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Lupus Nephritis: A Comparative Study Across Specialties

    JM JANSZ1, EA Troy2, WL Galanter3, Elaine Adams4, Nadera Sweiss5 and HJ CHANG6, 1University of Illinois at Chicago, Chicago, IL, 2University of Illinois at Chicago, Woodridge, IL, 3University of Illinois at Chicago; Jesse Brown VA Medical Center, CHICAGO, IL, 4Jesse Brown VA Medical Center, La Grange, IL, 5University of IL, Chicago, IL, 6RHEUMATOLOGIST, CHICAGO, IL

    Background/Purpose: Lupus nephritis is a well-known and severe complication in patients with systemic lupus erythematosus (SLE) that can lead to significant morbidity and mortality. Angiotensin-converting…
  • Abstract Number: 1870 • ACR Convergence 2024

    Costs and Healthcare Resource Utilization Associated with Inpatient and Day Hospitalizations of Patients with Lupus and Psychiatric Manifestations in France

    Nicoleta Petrica1, Nathan Cohen1, Maria Pini1, Minjee Park2, Mathieu Rosé3 and Jean-Francois Ricci2, 1Alira Health, Paris, France, 2Alira Health, Basel, Switzerland, 3Alira Health, Barcelone, Spain

    Background/Purpose: Lupus, a rare chronic autoimmune disorder, severely impacts patients' quality of life, productivity, and survival, placing a heavy burden on the healthcare system. Up…
  • Abstract Number: 2575 • ACR Convergence 2024

    Can Immunosuppressive Therapy Be Safely Discontinued in Patients with Lupus Nephritis?

    Paola Vidal1, Javier Narvaez-García2, Francesc-Xavier Fulladosa2, Francesca Mitjavila2, olga Capdevila2, Pol Maymó3, Judith Palacios4 and Joan Miquel Nolla2, 1Hospital Universtiario de Bellvitge, Barcelona, Spain, 2Hospital Universitario de Bellvitge, Barcelona, Spain, 3Hospital Universitario de Bellvitge., Barcelona, Spain, 4Bellvitge University Hospital, L'Hospitalet de Llobregat, Catalonia, Spain

    Background/Purpose: The latest guidelines for managing lupus nephritis (LN), including the 2024 KDIGO guidelines and the 2019 EULAR/ERA-EDTA update, recommend a minimum immunosuppression (IS) duration…
  • Abstract Number: 0018 • ACR Convergence 2024

    Preclinical Analysisof CB-010, an Allogeneic anti-CD19CAR-T Cell Therapywith a PD-1 Knockout, for the Treatment of Patients with Refractory Systemic Lupus Erythematosus (SLE)

    Elizabeth Garner, George Kwong, Tristan W Fowler, Heinrich Kufeldt, Brian Kerfs, Julie Kim, Art Aviles, Lynne Alexander, Franco Davi, Chris Holland, Jean-Yves Maziere, Ashraf Garrett, Mara Bryan, Linh Chu, Sarbani Bhaduri, Michele Gerber, Elaine Alambra, Justin Skoble, Tom Kochy, Tonia Nesheiwat, Socorro Portella, Enrique Zudaire and Steven B Kanner, Caribou Biosciences, Berkeley, CA

    Background/Purpose: Autologous CD19-directed CAR-T cell therapy has been shown to eradicate aberrant B cells leading to durable clinical responses in SLE patients (Müller 2024; Wang 2024). However, autologous CAR-T cell…
  • Abstract Number: 0646 • ACR Convergence 2024

    Chart Audit of over 1,000 SLE Patients Reveals Biologic Treatment Choice Driven by Disease Manifestations

    Maxine Yarnall1, Ryan Rex2 and Sawyer May1, 1Spherix Global Insights, Exton, PA, 2Spherix Global Insights, Chester Springs, PA

    Background/Purpose: To better understand how US rheumatologists utilize biologics in the management of SLE, especially among those with cutaneous manifestations. No medication is currently FDA-approved…
  • Abstract Number: 0812 • ACR Convergence 2024

    A Human Gut Pathobiont Drives Platelet Activation with Microparticle Release and NETosis During Lupus Nephritis Flares

    Abhimanyu Amarnani1, Cristobal Rivera-Martinez1, Marc Scherlinger2, Doua Azzouz1, Andy Lee1, Kate Trujillo1, MacIntosh Cornwell1, Tyler Weinstein1, Tatiana Borja3, Bharati Matta4, Sharon Chung5, Laura Cooney6, Uzair Chaudhary1, Steven Medvedovsky1, Peter Izmirly1, Jill Buyon1, Patrick Blanco7, Betsy Barnes8, Bhama Ramkhelawon1, Kelly Ruggles9 and Gregg Silverman1, 1New York University Grossman School of Medicine, New York, NY, 2Strasbourg University Hospital, Strasbourg, France, 3Feinstein Institutes for Medical Research, New York, NY, 4The Feinstein Institutes for Medical Research, Manhasset, NY, 5University of California, San Francisco and Immune Tolerance Network, San Francsico, 6University of Michigan and Immune Tolerance Network, Ann Arbor, MI, 7UMR_CNRS 5164 Immunoconcept, BORDEAUX CEDEX, France, 8Feinstein Institutes for Medical Science, Manhasset, NY, 9NYU Grossman School of Medicine, Brooklyn, NY

    Background/Purpose: SLE is a leading cause of premature death, often from severe complications including lupus nephritis (LN), especially in disadvantaged groups. Despite advances in treatment,…
  • Abstract Number: 1538 • ACR Convergence 2024

    Patient Reported Outcomes Analyses from AURORA 1 Clinical Trial: Lupus Impact Tracker and LupusPRO

    Meenakshi Jolly1, Matt Truman2, Ronald Flauto3 and Kathryn Dao4, 1Rush University, Chicago, IL, 2Aurinia Pharmaceuticals, Victoria, BC, Canada, 3Aurinia Pharmaceuticals, Rockville, MD, 4Rheum101, Rockville, MD

    Background/Purpose: Voclosporin used in addition to Mycophenolate Mofetil and low dose oral steroids in patients with active Lupus Nephritis (LN) was found to be superior…
  • Abstract Number: 1873 • ACR Convergence 2024

    Race/Ethnicity and Household Income at the County Level Interacts with the Association of Urbanicity and Lupus Nephritis Mortality

    Snehin Rajkumar1, Eric Yen2 and Ram Singh3, 1UCLA David Geffen School of Medicine, Irvine, CA, 2UCLA, Los Angeles, CA, 3UCLA David Geffen School of Medicine, Los Angeles, CA

    Background/Purpose: The reasons underlying substantial variation in lupus nephritis (LN) deaths by race/ethnicity remain largely unknown. There are no large population-based studies focused on the…
  • Abstract Number: 2576 • ACR Convergence 2024

    Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients with Systemic Lupus Erythematosus and Lupus Nephritis

    April Jorge1, Aakash Patel1, Baijun Zhou2, Yuqing Zhang3 and Hyon K. Choi4, 1Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Massachusetts General Hospital, Boston, MA, 3Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School; The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 4Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are hypoglycemic agents with well-established cardioprotective properties and emerging data for kidney-protective benefits in patients with type 2 diabetes…
  • Abstract Number: 0085 • ACR Convergence 2024

    A Novel, Potent and Selective TLR7/8 Small Molecule Inhibitor Blocks TLR7/8 Pathway in the Presence of HCQ and Demonstrates Robust Preclinical Efficacy in Lupus Models

    Ching Shang1, Angie Hammond2, Yuanjiang Yu1, Bing Xia1, Yew Ann Leong1, Emily Chung1, zhiyu Huang1, Paqui Gonzalez Traves3, Wesley Minto1, Sunish Mohanan1, Hailing Zong1, Gundula Min-oo1, Stephen Ammann4, Eda Canales5 and Natasha Crellin3, 1Gilead Sciences, Foster City, CA, 2Gilead Sciences, Inc., Seattle, WA, 3Gilead, Foster City, CA, 4Gilead Sciences, Foster City, 5Gilead Sciences, San Mateo, CA

    Background/Purpose: Toll-like receptor 7, 8 and 9 (TLR7/8/9) are endosomal nucleic acid sensors that when aberrantly activated, induce Type I interferon (IFNα), proinflammatory cytokines, immune…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 37
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology